Humanized docking system for assembly of targeting drug delivery complexes

被引:16
作者
Backer, MV
Gaynutdinov, TI
Gorshkova, II
Crouch, RJ
Hu, T
Aloise, R
Arab, M
Przekop, K
Backer, JA
机构
[1] SibTech Inc, Newington, CT 06111 USA
[2] NICHHD, Mol Genet Lab, NIH, Bethesda, MD 20892 USA
关键词
targeted delivery; assembled targeting complexes; vascular endothelial growth factor; human RNase; gene therapy;
D O I
10.1016/S0168-3659(03)00150-0
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Targeted drug delivery requires loading' drugs onto targeting proteins. Traditional technologies for loading drugs rely on I chemical conjugation of drugs or drug carriers to targeting proteins. An alternative approach might rely on assembly of targeting complexes using a docking system that includes two components: a 'docking' tag fused to a targeting protein, and a 'payload' module containing an adapter protein for non-covalent binding to the docking tag. We describe here a fully humanized adapter/docking tag system based on non-covalent interaction between two fragments of human pancreatic RNase I. A 15 amino acid long N-terminal fragment of RNase I designed to serve as a docking tag, was fused to the N-terminus of human vascular endothelial growth factor that served as a targeting protein. An 18-125 and an 18-127 amino acid long fragments of RNase I were engineered, expressed and refolded into active conformations to serve as adapter proteins. Interactions between the targeting and adapter proteins were characterized using enzymatic analysis and surface plasmon resonance. Targeting DNA delivery complexes were assembled, characterized by dynamic light scattering, and found to be very effective in receptor-mediated DNA delivery. (C) 2003 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:499 / 511
页数:13
相关论文
共 25 条
[1]   Engineering S-protein fragments of bovine ribonuclease A for targeted drug delivery [J].
Backer, MV ;
Gaynutdinov, TI ;
Aloise, R ;
Przekop, K ;
Backer, JM .
PROTEIN EXPRESSION AND PURIFICATION, 2002, 26 (03) :455-461
[2]   Molecular vehicles for targeted drug delivery [J].
Backer, MV ;
Aloise, R ;
Przekop, K ;
Stoletov, K ;
Backer, JM .
BIOCONJUGATE CHEMISTRY, 2002, 13 (03) :462-467
[3]   Functionally active VEGF fusion proteins [J].
Backer, MV ;
Backer, JM .
PROTEIN EXPRESSION AND PURIFICATION, 2001, 23 (01) :1-7
[4]   Targeting endothelial cells overexpressing VEGFR-2: Selective toxicity of Shiga-like toxin-VEGF fusion proteins [J].
Backer, MV ;
Backer, JM .
BIOCONJUGATE CHEMISTRY, 2001, 12 (06) :1066-1073
[5]   A VERSATILE VECTOR FOR GENE AND OLIGONUCLEOTIDE TRANSFER INTO CELLS IN CULTURE AND IN-VIVO - POLYETHYLENIMINE [J].
BOUSSIF, O ;
LEZOUALCH, F ;
ZANTA, MA ;
MERGNY, MD ;
SCHERMAN, D ;
DEMENEIX, B ;
BEHR, JP .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (16) :7297-7301
[6]  
BROWN LF, 1993, AM J PATHOL, V143, P1255
[7]   EXPRESSION OF VASCULAR-PERMEABILITY FACTOR (VASCULAR ENDOTHELIAL GROWTH-FACTOR) AND ITS RECEPTORS IN BREAST-CANCER [J].
BROWN, LF ;
BERSE, B ;
JACKMAN, RW ;
TOGNAZZI, K ;
GUIDI, AJ ;
DVORAK, HF ;
SENGER, DR ;
CONNOLLY, JL ;
SCHNITT, SJ .
HUMAN PATHOLOGY, 1995, 26 (01) :86-91
[8]   THERMODYNAMICS OF PROTEIN PEPTIDE INTERACTIONS IN THE RIBONUCLEASE-S SYSTEM STUDIED BY TITRATION CALORIMETRY [J].
CONNELLY, PR ;
VARADARAJAN, R ;
STURTEVANT, JM ;
RICHARDS, FM .
BIOCHEMISTRY, 1990, 29 (25) :6108-6114
[9]  
Dübel S, 1999, TUMOR TARGET, V4, P37
[10]   Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs [J].
Dubowchik, GM ;
Walker, MA .
PHARMACOLOGY & THERAPEUTICS, 1999, 83 (02) :67-123